Skip to main content
OpenTrials
Completed

NCT Number: NCT02817230

Effect of Statins on Trained Immunity

In this study, the investigators will determine whether patients with elevated levels of LDL are characterized by specific epigenetic changes in circulating cells of the innate immune system, compared to control subjects with healthy levels of LDL and whether regular statin treatment influences these changes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Loading trial locations.

About this study

Rationale: The innate immune system plays a pivotal role in the development and progression of atherosclerosis. Recently, it was reported that monocytes can develop a long-lasting immunological memory after stimulation with various microorganisms, which has been termed 'trained innate immunity'. This memory is induced by epigenetic reprogramming. Here the investigators hypothesize that monocytes of patients with elevated LDL cholesterol levels show epigenetic changes compared to normocholesterolemic subjects and that this can be reversed by treatment with statins.

Objective: The main objective is to study whether patients with elevated levels of LDL show increased Histone 3 Lysine 4 trimethylation in the promoter regions of pro-inflammatory cytokines and have an augmented ex vivo Toll-Like Receptor agonist-induced cytokine production in isolated monocytes compared to controls. Subsequently the investigators will study the effect of treatment with statins on these responses.

Study design: Observational study Study population: Subjects aged >18 years who have been referred to the out-patient clinic and have LDL levels that require lipid lowering treatment and matched normocholesterolemic control subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients:

  • 18 years or older
  • Elevated LDL levels (>4.9 mmol/l)
  • No previous cardiovascular events

Controls:

  • Age > 18 years
  • LDL cholesterol < 3.5 mmol/l
  • No previous cardiovascular events

Exclusion criteria

  • Current lipid lowering treatment
  • Known malignant disorders, auto-immune disorder, or diabetes
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study
  • Clinical signs of acute infection
  • Use of anti-inflammatory medication

Treatment and study plan

Statin

Drug

Primary outcomes

  1. Changes in histone methylation levels in circulating monocytes

    Time frame: Baseline-3 months follow up

    Histone methylation levels on different lysines of histone 3 will be analyzed at baseline and after 3 months of statin treatment

Secondary outcomes

  1. Inflammatory phenotype

    Time frame: Baseline-3 months follow up

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • Erasmus Medical Center

Registry information

Official study title

Effect of Statins on Epigenetic Reprogramming of Monocytes in Patients With Elevated Levels of LDL

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Jun 29, 2016
Registry last updated
Nov 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.